CES1
Basic information
Region (hg38): 16:55802851-55833337
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Drug metabolism, altered, CES1-related (Carboxylesterase 1 deficiency) | AD/AR | Pharmacogenomic | Selection and dosing of certain medications may be affected by the presence of variants | Biochemical | 18485328; 23111421; 26817948; 27614009; 28087982 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CES1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 42 | 44 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 42 | 2 | 0 |
Variants in CES1
This is a list of pathogenic ClinVar variants found in the CES1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-55810528-C-T | not specified | Uncertain significance (Jul 26, 2021) | ||
16-55810529-G-C | not specified | Uncertain significance (Mar 21, 2024) | ||
16-55810597-T-C | not specified | Uncertain significance (Dec 14, 2023) | ||
16-55810604-T-C | not specified | Uncertain significance (Aug 22, 2023) | ||
16-55810627-T-A | not specified | Uncertain significance (Nov 25, 2024) | ||
16-55810937-T-C | not specified | Uncertain significance (Aug 11, 2024) | ||
16-55810965-T-A | not specified | Uncertain significance (Apr 06, 2024) | ||
16-55810997-T-C | not specified | Conflicting classifications of pathogenicity (Jun 01, 2024) | ||
16-55811002-C-T | not specified | Uncertain significance (Sep 26, 2024) | ||
16-55812941-C-T | not specified | Uncertain significance (Feb 03, 2022) | ||
16-55812956-C-A | not specified | Uncertain significance (Jun 22, 2021) | ||
16-55812976-G-C | not specified | Uncertain significance (Dec 04, 2024) | ||
16-55816928-C-T | not specified | Uncertain significance (Jan 26, 2023) | ||
16-55816931-G-T | not specified | Uncertain significance (Oct 01, 2024) | ||
16-55819548-G-A | not specified | Uncertain significance (Aug 01, 2022) | ||
16-55819602-G-A | not specified | Uncertain significance (Jul 14, 2024) | ||
16-55819609-T-C | not specified | Uncertain significance (Aug 10, 2024) | ||
16-55819630-T-C | not specified | Likely benign (Mar 25, 2024) | ||
16-55820389-CA-C | DRUG METABOLISM, ALTERED, CES1-RELATED | Pathogenic (Jun 01, 2008) | ||
16-55821400-C-T | not specified | Uncertain significance (Feb 21, 2024) | ||
16-55821502-G-A | not specified | Uncertain significance (Jan 24, 2024) | ||
16-55821517-C-G | not specified | Uncertain significance (May 24, 2024) | ||
16-55823593-C-T | not specified | Uncertain significance (Dec 18, 2023) | ||
16-55823599-C-T | not specified | Uncertain significance (Sep 30, 2024) | ||
16-55823611-C-T | not specified | Uncertain significance (Dec 04, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CES1 | protein_coding | protein_coding | ENST00000360526 | 14 | 30487 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.32e-15 | 0.0106 | 118876 | 6 | 6866 | 125748 | 0.0277 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -2.00 | 307 | 223 | 1.38 | 0.0000124 | 3604 |
Missense in Polyphen | 98 | 72.254 | 1.3563 | 1185 | ||
Synonymous | -3.37 | 130 | 89.4 | 1.45 | 0.00000543 | 1103 |
Loss of Function | -0.0859 | 22 | 21.6 | 1.02 | 0.00000112 | 319 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0624 | 0.0619 |
Ashkenazi Jewish | 0.0225 | 0.0227 |
East Asian | 0.0628 | 0.0637 |
Finnish | 0.0110 | 0.0110 |
European (Non-Finnish) | 0.0173 | 0.0174 |
Middle Eastern | 0.0628 | 0.0637 |
South Asian | 0.0429 | 0.0433 |
Other | 0.0290 | 0.0291 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate. {ECO:0000269|PubMed:7980644, ECO:0000269|PubMed:9169443}.;
- Pathway
- Drug metabolism - other enzymes - Homo sapiens (human);Fluoropyrimidine Pathway, Pharmacokinetics;Clopidogrel Pathway, Pharmacokinetics;Mycophenolic acid Pathway, Pharmacokinetics;Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics;Irinotecan Pathway, Pharmacokinetics;Irinotecan Pathway, Pharmacodynamics;Mycophenolic Acid Metabolism Pathway;Capecitabine Action Pathway;Heroin Metabolism Pathway;Irinotecan Action Pathway;Capecitabine Metabolism Pathway;Heroin Action Pathway;Irinotecan Metabolism Pathway;Phase I biotransformations, non P450;Fluoropyrimidine Activity;Irinotecan Pathway;Heroin metabolism;Nuclear Receptors Meta-Pathway;NRF2 pathway;Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling;Phase I - Functionalization of compounds;Biological oxidations;Metabolism;retinol biosynthesis;E2F transcription factor network
(Consensus)
Recessive Scores
- pRec
- 0.333
Intolerance Scores
- loftool
- 0.954
- rvis_EVS
- 1.91
- rvis_percentile_EVS
- 97.43
Haploinsufficiency Scores
- pHI
- 0.472
- hipred
- N
- hipred_score
- 0.153
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.988
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ces1h
- Phenotype
Gene ontology
- Biological process
- cholesterol biosynthetic process;xenobiotic metabolic process;response to toxic substance;lipid catabolic process;epithelial cell differentiation;medium-chain fatty acid metabolic process;cholesterol ester hydrolysis involved in cholesterol transport
- Cellular component
- extracellular space;endoplasmic reticulum;endoplasmic reticulum lumen;cytosol
- Molecular function
- sterol esterase activity;triglyceride lipase activity;methylumbelliferyl-acetate deacetylase activity;carboxylic ester hydrolase activity